Advertisement
UK markets open in 2 hours 49 minutes

  • NIKKEI 225

    38,708.92
    -146.45 (-0.38%)
     

  • HANG SENG

    18,529.63
    -291.53 (-1.55%)
     

  • CRUDE OIL

    80.11
    +0.28 (+0.35%)
     

  • GOLD FUTURES

    2,358.90
    +2.40 (+0.10%)
     

  • DOW

    38,852.86
    -216.74 (-0.55%)
     

  • Bitcoin GBP

    53,904.26
    +572.08 (+1.07%)
     

  • CMC Crypto 200

    1,451.77
    -44.69 (-2.99%)
     

  • NASDAQ Composite

    17,019.88
    +99.08 (+0.59%)
     

  • UK FTSE All Share

    4,506.79
    -31.23 (-0.69%)
     
Money:

What's next for state pension? Sunak unveils 'Triple Lock Plus'

The Triple Lock Plus would introduce a new age-related allowance for pensioners

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation
·2-min read
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

  • The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET

  • H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET

To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

ADVERTISEMENT

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com